Tumor promotion through the mesenchymal stem cell compartment in human hepatocellular carcinoma

Carcinogenesis

Volumn 34, Issue 10, 2013, Pages 2330-2340

  Hernanda, Pratika Y ^a   Pedroza Gonzalez, Alexander ^a   van der Laan, Luc J W ^a   Bröker, Mirelle E E ^a   Hoogduijn, Martin J ^a   Ijzermans, Jan N M ^a   Bruno, Marco J ^a   Janssen, Harry L A ^a,b   Peppelenbosch, Maikel P ^a   Pan, Qiuwei ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPOCYTE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL INFILTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; OSTEOCYTE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR PROMOTION; TUMOR VOLUME; UPREGULATION;

ANIMALS; ANTIGENS, SURFACE; CARCINOMA, HEPATOCELLULAR; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; HETEROGRAFTS; HUMANS; LIVER NEOPLASMS; MESENCHYMAL STROMAL CELLS; MICE; TUMOR BURDEN; TUMOR STEM CELL ASSAY;

EID: 84885133530     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgt210     Document Type: Article

References (48)

1. Aquino, J.B. et al. (2010) Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. Gene Ther., 17, 692-708.
2. Chen, X.C. et al. (2006) Prophylaxis against carcinogenesis in three kinds of unestablished tumor models via IL12-gene-engineered MSCs. Carcinogenesis, 27, 2434-2441.
3. Matar, P. et al. (2009) Immunotherapy for liver tumors: present status and future prospects. J. Biomed. Sci., 16, 30.
4. Llovet, J.M. et al. (2008) Molecular targeted therapies in hepatocellular carcinoma. Hepatology, 48, 1312-1327.
5. Théret, N. et al. (2001) Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology, 34, 82-88.
6. Hanahan, D. et al. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
7. Holz, L.E. et al. (2008) Liver tolerance and the manipulation of immune outcomes. Inflamm. Allergy Drug Targets, 7, 6-18.
8. Friedenstein, A.J. et al. (1974) Precursors for fibroblasts in different populations of hematopoietic cells as detected by the in vitro colony assay method. Exp. Hematol., 2, 83-92.
9. Keating, A. (2012) Mesenchymal stromal cells: new directions. Cell Stem Cell, 10, 709-716.
10. Gao, Z. et al. (2013) Mesenchymal stem cells: a potential targeted-delivery vehicle for anti-cancer drug, loaded nanoparticles. Nanomedicine, 9, 174-184.
11. Dai, L.J. et al. (2011) Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett., 305, 8-20.
12. Khakoo, A.Y. et al. (2006) Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma. J. Exp. Med., 203, 1235-1247.
13. Qiao, L. et al. (2008) Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res., 18, 500-507.
14. Zhu, Y. et al. (2009) Human mesenchymal stem cells inhibit cancer cell proliferation by secreting DKK-1. Leukemia, 23, 925-933.
15. Karnoub, A.E. et al. (2007) Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature, 449, 557-563.
16. Galiè, M. et al. (2008) Mesenchymal stem cells share molecular signature with mesenchymal tumor cells and favor early tumor growth in syngeneic mice. Oncogene, 27, 2542-2551.
17. Kucerova, L. et al. (2010) Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer, 9, 129.
18. Yan, X.L. et al. (2013) Hepatocellular carcinoma-associated mesenchymal stem cells promote hepatocarcinoma progression: role of the S100A4-miR155-SOCS1-MMP9 axis. Hepatology. doi:10.1002/hep.26257.
19. Klopp, A.H. et al. (2011) Concise review: Dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth. Stem Cells, 29, 11-19.
20. Pan, Q. et al. (2011) Mobilization of hepatic mesenchymal stem cells from human liver grafts. Liver Transpl., 17, 596-609.
21. Pedroza-Gonzalez, A. et al. (2013) Activated tumor-infiltrating CD4+ regulatory T cells restrain antitumor immunity in patients with primary or metastatic liver cancer. Hepatology, 57, 183-194.
22. Lin, Y. et al. (1995) Differential in situ hybridization for determination of mutational specific expression of the p53 gene in human hepatoma cell lines. Pathology, 27, 191-196.
23. Pan, Q. et al. (2008) Synergistic antitumor activity of XIAP-shRNA and TRAIL expressed by oncolytic adenoviruses in experimental HCC. Acta Oncol., 47, 135-144.
24. Kolf, C.M. et al. (2007) Mesenchymal stromal cells. Biology of adult mesenchymal stem cells: regulation of niche, self-renewal and differentiation. Arthritis Res. Ther., 9, 204.
25. Ning, H. et al. (2011) Mesenchymal stem cell marker Stro-1 is a 75 kd endothelial antigen. Biochem. Biophys. Res. Commun., 413, 353-357.
26. D'Souza, N., et al. (2012) MSC and tumors: homing, differentiation and secretion influence the therapeutic potentials. Adv Biochem Eng Biotechnol. doi:10.1007/10_2012_150
27. Vogel, S. et al. (2013) Migration of mesenchymal stem cells towards glioblastoma cells depends on hepatocyte-growth factor and is enhanced by aminolaevulinic acid-mediated photodynamic treatment. Biochem. Biophys. Res. Commun., 431, 428-432.
28. Ogunwobi, O.O. et al. (2011) Hepatocyte growth factor upregulation promotes carcinogenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via Akt and COX-2 pathways. Clin. Exp. Metastasis, 28, 721-731.
29. Senst, C. et al. (2013) Prospective dual role of mesenchymal stem cells in breast tumor microenvironment. Breast Cancer Res. Treat., 137, 69-79.
30. Al-Khaldi, A. et al. (2003) Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther., 10, 621-629.
31. Roorda, B.D. et al. (2009) Bone marrow-derived cells and tumor growth: contribution of bone marrow-derived cells to tumor micro-environments with special focus on mesenchymal stem cells. Crit. Rev. Oncol. Hematol., 69, 187-198.
32. Tsai, K.S. et al. (2011) Mesenchymal stem cells promote formation of colorectal tumors in mice. Gastroenterology, 141, 1046-1056.
33. Biancone, L. et al. (2012) Therapeutic potential of mesenchymal stem cellderived microvesicles. Nephrol. Dial. Transplant, 27, 3037-3042.
34. Roccaro, A.M. et al. (2013) BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J. Clin. Invest., 123, 1542-1555.
35. Zhu, W. et al. (2012) Exosomes derived from human bone marrow mesenchymal stem cells promote tumor growth in vivo. Cancer Lett., 315, 28-37.
36. Katakowski, M. et al. (2013) Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett., 335, 201-204.
37. Bruno, S. et al. (2013) Microvesicles derived from human bone marrow mesenchymal stem cells inhibit tumor growth. Stem Cells Dev., 22, 758-771.
38. Hass, R. et al. (2012) Mesenchymal stem cells as all-round supporters in a normal and neoplastic microenvironment. Cell Commun. Signal., 10, 26.
39. Raicevic, G. et al. (2010) Inflammation modifies the pattern and the function of Toll-like receptors expressed by human mesenchymal stromal cells. Hum. Immunol., 71, 235-244.
40. Waterman, R.S. et al. (2010) A new mesenchymal stem cell (MSC) paradigm: polarization into a pro-inflammatory MSC1 or an Immunosuppressive MSC2 phenotype. PLoS One, 5, e10088.
41. Dayan, V. et al. (2011) Mesenchymal stromal cells mediate a switch to alternatively activated monocytes/macrophages after acute myocardial infarction. Basic Res. Cardiol., 106, 1299-1310.
42. Waterman, R.S. et al. (2012) Mesenchymal stem cell 1 (MSC1)-based therapy attenuates tumor growth whereas MSC2-treatment promotes tumor growth and metastasis. PLoS One, 7, e45590.
43. Terai, S. et al. (2006) Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells, 24, 2292-2298.
44. El-Ansary, M. et al. (2012) Phase II trial: undifferentiated versus differentiated autologous mesenchymal stem cells transplantation in Egyptian patients with HCV induced liver cirrhosis. Stem Cell Rev., 8, 972-981.
45. Popp, F.C. et al. (2011) Safety and feasibility of third-party multipotent adult progenitor cells for immunomodulation therapy after liver transplantation- a phase I study (MISOT-I). J. Transl. Med., 9, 124.
46. El-Serag, H.B. (2012) Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology, 142, 1264-1273.e1.
47. Samuel, D. et al. (2011) Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma. Liver Transpl., 17 (suppl. 2), S6-S13.
48. Tjon, A.S. et al. (2010) Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age. Liver Transpl., 16, 837-846.